CCAB Signs Collaboration and License Agreement With Pionyr Immunotherapeutics Inc. to Discover Antibody Drug Development Candidates TORONTO, April 03, 2017 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB), through the University of Toronto, has granted a non-exclusive license to Pionyr...